✦ LIBER ✦

PCV45 COST-UTILITY ANALYSIS OF RIMONABANT IN THE MANAGEMENT OF OBESITY/OVERWEIGHT PATIENTS WITH CARDIOMETABOLIC RISK FACTORS IN HUNGARY

✍ Scribed by B Nagy; K Borsos; G Blaskó

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

We-W42:3 Rimonabant improves cardiometab

✍ Després, J.P.; Van Gaal, L.; Scheen, A.; Pi-Sunyer, F.X. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 158 KB

CV4 ASSESSING COST-EFFECTIVENESS BEFORE

✍ JJ Caro; D Getsios; I Proskorovsky; C Nicholls; P McEwan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PDB27 A COST-UTILITY ANALYSIS OF ORLISTA

✍ JM Sverre; FKO Kristensen; LB Holm; K Nyhus 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN67 COST UTILITY ANALYSIS OF ALEMTUZUM

✍ AC Lloyd; A Valderrama; J Ferguson; L Gilmour; F Ravndal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

Interim analysis of the effects of exena

✍ L. Blonde; E. J. Klein; J. Han; B. Zhang; S. M. Mac; T. H. Poon; K. L. Taylor; M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Dabigatran versus warfarin under standar

✍ Nshimyumukiza, Léon; Duplantie, Julie; Gagnon, Mathieu; Douville, Xavier; Fourni 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 276 KB